In vitro analysis of cidofovir and genetically engineered TK expression as potential approaches for the intervention of ColoAd1-based treatment of cancer

Gene Therapy

Volumn 16, Issue 9, 2009, Pages 1169-1174

  Bauzon, M ^a   Jin, F ^a   Kretschmer, P ^a   Hermiston, T ^a  

^a BAYER CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CIDOFOVIR; GANCICLOVIR; PRODRUG; RIBAVIRIN; THYMIDINE KINASE;

ANTIVIRAL ACTIVITY; ARTICLE; CANCER GENE THERAPY; CONTROLLED STUDY; DRUG POTENCY; GENETIC ENGINEERING; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; INFECTION CONTROL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VALIDATION PROCESS; VIRAL GENE DELIVERY SYSTEM; VIRUS GENOME; VIRUS INFECTION;

ADENOVIRIDAE; ADENOVIRIDAE INFECTIONS; ANTIVIRAL AGENTS; CELL SURVIVAL; CELLS, CULTURED; CYTOSINE; GENETIC ENGINEERING; HUMANS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PHOSPHONIC ACIDS; PRODRUGS; RIBAVIRIN; THYMIDINE KINASE; TUMOR CELLS, CULTURED;

ADENOVIRIDAE; SIMPLEXVIRUS;

EID: 70249099553     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2009.69     Document Type: Article

References (28)

1. Kuhn I, Harden P, Bauzon M, Chartier C, Nye J, Thorne S et al. Directed evolution generates a novel oncolytic virus for the treatment of colon cancer. PLoS ONE 2008; 3: E2409.
2. Bell JC. Oncolytic viruses: What's next? Curr Cancer Drug Targets 2007; 7: 127-131.
3. Lenaerts L, Naesens L. Antiviral therapy for adenovirus infections. Antiviral Res 2006; 71: 172-180.
4. Ljungman P. Viral infections: Current diagnosis and treatment. Hematol J 2004; 5 (Suppl 3): S63-S68.
5. Neofytos D, Ojha A, Mookerjee B, Wagner J, Filicko J, Ferber A et al Treatment of adenovirus disease in stem cell transplant recipients with cidofovir. Biol Blood Marrow Transplant 2007; 13: 74-81.
6. Baba M, Mori S, Shigeta S, De Clercq E. Selective inhibitory effect of (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine and 2′-nor-cyclic GMP on adenovirus replication in vitro. Antimicrob Agents Chemother 1987; 31: 337-339.
7. Morfin F, Dupuis-Girod S, Mundweiler S, Falcon D, Carrington D, Sedlacek P et al. In vitro susceptibility of adenovirus to antiviral drugs is species-dependent. Antivir Ther 2005; 10: 225-229.
8. Wildner O, Hoffmann D, Jogler C, Uberla K. Comparison of HSV-1 thymidine kinase-dependent and -independent inhibition of replication-competent adenoviral vectors by a panel of drugs. Cancer Gene Ther 2003; 10: 791-802.
9. Lankester AC, Heemskerk B, Claas EC, Schilham MW, Beersma MF, Bredius RG et al. Effect of ribavirin on the plasma viral DNA load in patients with disseminating adenovirus infection. Clin Infect Dis 2004; 38: 1521-1525.
10. Muller WJ, Levin MJ, Shin YK, Robinson C, Quinones R, Malcolm J et al Clinical and in vitro evaluation of cidofovir for treatment of adenovirus infection in pediatric hematopoietic stem cell transplant recipients. Clin Infect Dis 2005; 41: 1812-1816.
11. Naesens L, Laenarts L, Andrei G, Snoeck R, Van Beers D, Holy A et al Antiadenovirus activities of several classes of nucleoside and nucleotide analogues. Antimicrob Agents Chemother 2005; 49: 1010-1016.
12. Hartline CB, Gustin KM, Wan WB, Ciesla SL, Beadle JR, Hostetler KY et al. Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: activity against adenovirus replication in vitro. J Infect Dis 2005; 191: 396-399.
13. Hermiston T. Gene delivery from replication-selective viruses: Arming guided missiles in the war against cancer. J Clin Invest 2000; 105: 1169-1172.
14. Elion GB. The biochemistry and mechanism of action of acyclovir. J Antimicrob Chemother 1983; 12 (Suppl B): 9-17.
15. Mar EC, Chiou JF, Cheng YC, Huang ES. Human cytomegalovirus- induced DNA polymerase and its interaction with the triphosphates of 1-(2′-deoxy-2′-fluoro-beta-D-arabinofuranosyl)5- methyluracil, -5-iodocytosine, and -5-methylcytosine. J Virol 1985; 56: 846-851.
16. van Dillen IJ, Mulder NH, Vaalberg W, de Vries EF, Hospers GA. Influence of the bystander effect on HSV-tk/GCV gene therapy. A review. Curr Gene Ther 2002; 2: 307-322.
17. Holder JW, Elmore E, Barrett JC. Gap junction function and cancer. Cancer Res 1993; 53: 3475-3485.
18. Mesnil M, Piccoli C, Tiraby G, Willecke K, Yamasaki H. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc Natl Acad Sci USA 1996; 93: 1831-1835.
19. Touraine RL, Ishii-Morita H, Ramsey WJ, Blaese RM. The bystander effect in the HSVtk/ganciclovir system and its relationship to gap junctional communication. Gene Therapy 1998; 5: 1705-1711.
20. Trosko JE, Ruch RJ. Cell-cell communication in carcinogenesis. Front Biosci 1998; 3: D208-d236.
21. Tjuvajev JG, Doubrovin M, Akhurst T, Cai S, Balatoni J, Alauddin MM et al. Comparison of radiolabeled nucleoside probes (FIAU, FHBG, and FHPG) for PET imaging of HSV1-tk gene expression. J Nucl Med 2002; 43: 1072-1083.
22. Wang JQ, Fei X, Gardner TA, Hutchins GD, Zheng QH. Synthesis of 2-amino-6-(4-[11C]methoxyphenylthio)-9-[2-(phosphonomethoxy) ethyl]purine bis(2,2,2-trifluoroethyl) ester as a novel potential PET gene reporter probe for HBV and HSV-tk in cancers. Bioorg Med Chem 2005; 13: 549-556.
23. Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000; 6: 879-885.
24. Hawkins LK, Johnson L, Bauzon M, Nye JA, Castro D, Kitzes GA et al Gene delivery from the E3 region of replicating human adenovirus: evaluation of the 6.7 K/gp19K region. Gene Therapy 2001; 8: 1123-1131.
25. Tollefson A, Hermiston T, Wold WS. Preparation and titration of cesium chloride banded adenovirus stock. In: Wold WSM (ed). Adenovirus Methods and Protocols. Humana Press: Totowa, NJ, USA, 1999.
26. Shabram PW, Giroux DD, Goudreau AM, Gregory RJ, Horn MT, Huyghe BG et al. Analytical anion-exchange HPLC of recombinant type-5 adenoviral particles. Hum Gene Ther 1997; 8: 453-465.
27. Kuhn I, Larsen B, Gross C, Hermiston T. High-performance liquid chromatography method for rapid assessment of viral particle number in crude adenoviral lysates of mixed serotype. Gene Therapy 2007; 14: 180-184.
28. Kretschmer PJ, Jin F, Chartier C, Hermiston TW. Development of a transposon-based approach for identifying novel transgene insertion sites within the replicating adenovirus. Mol Ther 2005; 12: 118-127.